Generic Victoza Availability
Last updated on Jun 11, 2025.
Victoza is a brand name of liraglutide, approved by the FDA in the following formulation(s):
VICTOZA (liraglutide - solution;subcutaneous)
-
Manufacturer: NOVO NORDISK INC
Approval date: January 25, 2010
Strength(s): 18MG/3ML (6MG/ML) [RLD] [AP]
Is there a generic version of Victoza available?
A generic version of Victoza has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Victoza and have been approved by the FDA:
liraglutide solution;subcutaneous
-
Manufacturer: HIKMA
Approval date: December 23, 2024
Strength(s): 18MG/3ML (6MG/ML) [AP] -
Manufacturer: NANJING KING-FRIEND
Approval date: April 2, 2025
Strength(s): 18MG/3ML (6MG/ML) [AP]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Victoza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Patent 8,114,833
Issued: February 14, 2012
Inventor(s): Pedersen Tina Bjeldskov & Bonde Claude & Engelund Dorthe Kot
Assignee(s): Novo Nordisk A/SThe present invention relates to pharmaceutical formulations comprising a peptide and propylene glycol, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the peptide contained in such formulations is indicated. The present invention further relates to methods for reducing the clogging of injection devices by a peptide formulation and for reducing deposits on production equipment during production of a peptide formulation.
Patent expiration dates:
- August 13, 2025✓✓
- August 13, 2025
-
Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Patent 8114833*PED
Issued: February 14, 2012
Inventor(s): Pedersen Tina Bjeldskov & Bonde Claude & Engelund Dorthe Kot
Assignee(s): Novo Nordisk A/SThe present invention relates to pharmaceutical formulations comprising a peptide and propylene glycol, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the peptide contained in such formulations is indicated. The present invention further relates to methods for reducing the clogging of injection devices by a peptide formulation and for reducing deposits on production equipment during production of a peptide formulation.
Patent expiration dates:
- February 13, 2026✓
- February 13, 2026
-
Liraglutide in cardiovascular conditions
Patent 9,968,659
Issued: May 15, 2018
Inventor(s): Rasmussen Soeren
Assignee(s): Novo Nordisk A/SThe present invention relates to the GLP-1 receptor agonist liraglutide for use in medicine.
Patent expiration dates:
- January 9, 2037✓
- January 9, 2037
-
Liraglutide in cardiovascular conditions
Patent 9968659*PED
Issued: May 15, 2018
Inventor(s): Rasmussen Soeren
Assignee(s): Novo Nordisk A/SThe present invention relates to the GLP-1 receptor agonist liraglutide for use in medicine.
Patent expiration dates:
- July 9, 2037✓
- July 9, 2037
More about Victoza (liraglutide)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (766)
- Drug images
- Latest FDA alerts (4)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- FDA approval history
- Drug class: GLP-1 Agonists (Incretin Mimetics)
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Related/similar drugs
Trulicity
Trulicity is an injectable diabetes medicine that is used together with diet and exercise to ...
Lantus
Lantus is a long acting form of insulin used to treat type 1 or type 2 diabetes. Learn about side ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Tresiba
Tresiba (insulin degludec) is used to treat diabetes mellitus. Includes Tresiba side effects ...
Levemir
Levemir (insulin detemir) is a long acting insulin used to treat diabetes in adults and children ...
Novolog
NovoLog is a fast-acting insulin used to treat diabetes to control blood sugar levels in adults and ...
Basaglar
Basaglar (insulin glargine) is a long-acting insulin that is used to improve blood sugar control in ...
Soliqua
Soliqua 100/33 (insulin glargine and lixisenatide) is used to treat type 2 diabetes. Includes ...
Toujeo SoloStar
Toujeo (insulin glargine) is an injection used to treat type 1 or type 2 diabetes. Includes Toujeo ...
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
| AP | Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
